发明名称 Pharmaceutical formulation containing gelling agent
摘要 Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.
申请公布号 US9034376(B2) 申请公布日期 2015.05.19
申请号 US201414460134 申请日期 2014.08.14
申请人 Purdue Pharma L.P.;The P.F. Laboratories, Inc.;Purdue Pharmaceuticals L.P. 发明人 Wright Curtis;Oshlack Benjamin;Breder Christopher
分类号 A61K9/20;A61K31/167;A61K9/00;A61K31/439;A61K31/485;A61K47/38;A61K47/36;A61K47/10;A61K45/06;A61K31/192;A61K9/16;A61K47/26 主分类号 A61K9/20
代理机构 Lowenstein Sandler LLP 代理人 Lowenstein Sandler LLP
主权项 1. A controlled release oral solid dosage form comprising: a controlled release matrix comprising a mixture of (i) from 2.5 mg to 320 mg oxycodone or a pharmaceutically acceptable salt thereof; and (ii) a gelling agent comprising polyethylene oxide and hydroxypropylmethylcellulose, the gelling agent in an effective amount to impart a viscosity of at least 10 cP when the dosage form is subjected to tampering by dissolution in from 0.5 to 10 ml of an aqueous liquid; the controlled release matrix providing a therapeutic effect for at least 12 hours when orally administered to a human patient.
地址 Stamford CT US